Support for LAist comes from
Local and national news, NPR, things to do, food recommendations and guides to Los Angeles, Orange County and the Inland Empire
Stay Connected
Listen

Share This

News

President announces TrumpRx website for drugs and pricing deal with Pfizer

Four men wearing dark suits stand around a podium, smiling and laughing.
Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, (from left), Albert Bourla, CEO of Pfizer, President Donald Trump and Martin Makary, commissioner of the Food and Drug Administration, discuss a drug price initiative in the Oval Office on Tuesday.
(
Francis Chung
/
Politico/Bloomberg via Getty Images
)

Congress has cut federal funding for public media — a $3.4 million loss for LAist. We count on readers like you to protect our nonprofit newsroom. Become a monthly member and sustain local journalism.

President Donald Trump on Tuesday announced a deal with Pfizer to sell its drugs directly to consumers at discounted prices. They'll be available through a website operated by the federal government called TrumpRx.gov. He said similar deals with other drugmakers are in the works.

The new website is part of a broader initiative the administration says is aimed at bringing prices paid by Americans, including Medicaid patients, more in line with those paid in other developed countries. The idea is sometimes called most-favored-nation pricing. Under the deal, Pfizer agreed to charge the same price for new drugs in developed countries and the U.S.

"The American consumers have been subsidizing research and development for the entire planet," Trump said in a press conference, joined by his health team and Pfizer CEO Albert Bourla. "They put all of that on us, and yet they were the beneficiaries too. So it's been changed."

"I think today we are turning the tide, and we are reversing an unfair situation," Pfizer's Bourla said during the briefing.

Support for LAist comes from

The TrumpRx.gov website is expected to launch sometime in 2026 and would take consumers to pharmaceutical companies' direct-to-consumer websites to fulfill orders, according to senior administration officials who briefed reporters on the condition of anonymity.

Direct-to-consumer prices for Pfizer drugs on TrumpRx.gov will be 50% lower on average, according to a company press release. But there was a lack of important details on how the discounts were calculated. "Specific terms of the agreement remain confidential," the release said.

Discount website would be for patients not using insurance

Other countries mostly pay less for brand-name prescription drugs than the U.S. because they have government health systems that set drug prices. By and large, the U.S. doesn't set prices, so the drug companies can charge what the market will bear.

The website deals would only be accessible for patients not using their health insurance, according to one of the government officials briefing reporters anonymously. And even then, the discounted medicines might not be affordable because they're based on high drug list prices. Consumers with health insurance could very well pay less at the pharmacy counter.

As a result, the average consumer likely will not benefit from the Trump administration's deal, says Ameet Sarpatwari, an assistant professor of population medicine at Harvard Medical School who specializes in pharmaceutical policy.

Support for LAist comes from

"I think it's more underwhelming than what the president is touting," he says. "I think it's more window dressing than the transformational sort of reforms that are needed to really provide relief to Americans struggling with high prices."

Pfizer CEO Bourla also pledged to launch new drugs at the same price in the U.S. as in other developed countries and to offer drugs to Medicaid at most-favored-nation pricing, drawing praise from the Trump administration officials for being the first CEO to strike a deal.

"He really created a template for corporate responsibility, for putting public health ahead of his individual interests," said Health Secretary Robert F. Kennedy Jr.

Medicaid drug prices are already low

Sarpatwari says that since Medicaid often pays low prices for drugs anyway, and Medicaid beneficiaries pay very little for drugs, it's unclear whether this deal would benefit them or save taxpayers much money.

"It is an environment where you can pretend to make significant changes that actually don't meaningfully improve the prices that Americans will pay for their drugs," Sarpatwari says.

Tuesday's announcement follows the Trump Administration's executive order in May to lower drug prices. The president had promised to make other countries pay more for drugs. "So we're going to come down a lot, but the world is going to go up a little bit," he said during Tuesday's media briefing, explaining that it would make global drug prices more fair.

Support for LAist comes from

Over the summer, the Trump administration said it wasn't satisfied with what it was hearing from drug companies, so it sent letters to 17 of them with a list of demands, including lowering prices in Medicaid and launching new drugs at prices that match what people in other countries are paying. It also included selling drugs directly to consumers at lower prices.

Drugmakers had 60 days to do this voluntarily, or, the letter stated, "if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices."

The bargaining included the threat of tariffs stemming from an ongoing investigation into whether pharmaceutical imports posed a threat to national security. The deal with Pfizer includes a three-year grace period from those tariffs, and its CEO said the company would invest $70 billion to reshore manufacturing of drugs sold domestically. Of tariffs, Bourla said, the "president is absolutely right. It is the most powerful tool to motivate behaviors."
Copyright 2025 NPR

As Editor-in-Chief of our newsroom, I’m extremely proud of the work our top-notch journalists are doing here at LAist. We’re doing more hard-hitting watchdog journalism than ever before — powerful reporting on the economy, elections, climate and the homelessness crisis that is making a difference in your lives. At the same time, it’s never been more difficult to maintain a paywall-free, independent news source that informs, inspires, and engages everyone.

Simply put, we cannot do this essential work without your help. Federal funding for public media has been clawed back by Congress and that means LAist has lost $3.4 million in federal funding over the next two years. So we’re asking for your help. LAist has been there for you and we’re asking you to be here for us.

We rely on donations from readers like you to stay independent, which keeps our nonprofit newsroom strong and accountable to you.

No matter where you stand on the political spectrum, press freedom is at the core of keeping our nation free and fair. And as the landscape of free press changes, LAist will remain a voice you know and trust, but the amount of reader support we receive will help determine how strong of a newsroom we are going forward to cover the important news from our community.

Please take action today to support your trusted source for local news with a donation that makes sense for your budget.

Thank you for your generous support and believing in independent news.

Chip in now to fund your local journalism
A row of graphics payment types: Visa, MasterCard, Apple Pay and PayPal, and  below a lock with Secure Payment text to the right
(
LAist
)

Trending on LAist